Transcriptome-wide analysis of alternative mRNA splicing signature in the diagnosis and prognosis of stomach adenocarcinoma

Shi,Yu; Chen,Zuhua; Gao,Juanjuan; Wu,Si; Gao,Haer; Feng,Guoshuang

doi:10.3892/or.2018.6623

Transcriptome-wide analysis of alternative mRNA splicing signature in the diagnosis and prognosis of stomach adenocarcinoma

Authors:
- Yu Shi
- Zuhua Chen
- Juanjuan Gao
- Si Wu
- Haer Gao
- Guoshuang Feng
View Affiliations

Affiliations: National Clinical Research Center of Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Department of Cancer Epidemiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, P.R. China
Published online on: August 2, 2018 https://doi.org/10.3892/or.2018.6623
Pages: 2014-2022
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alternative mRNA splicing (AS) contributes greatly to expanding the diversity and function of the proteome. Increasing evidence has suggested that dysregulation of mRNA splicing may be associated with various types of cancer. In the present study, RNA sequencing data were used to investigate alterations to the global mRNA splicing landscape of cellular genes from 452 stomach adenocarcinoma (STAD) tissues available in The Cancer Genome Atlas. Seven types of AS events, including the profiles of exon skipping events, were analyzed using SpliceSeq software. A total of 60,754 AS events in 10,611 genes were detected, more than half of which were exon skipping events. The AS events were compared between 415 STAD tissues and 37 normal tissues, and 3,895 differentially spliced cancer-specific events were identified. In addition, the association of the AS events with the overall survival of 373 STAD patients was analyzed. Multivariate Cox regression analysis revealed that prognosis prediction models based on the AS events with clinical parameters had an excellent performance in predicting the survival of STAD patients. This study provides a comprehensive portrait of global changes in mRNA splicing signatures that occur in gastric cancer. These results allowed the identification of a core set of AS in gastric cancer and indicated that AS events may serve as prognostic indicators.

View Figures

View References

1	Nilsen TW and Graveley BR: Expansion of the eukaryotic proteome by alternative splicing. Nature. 463:457–463. 2010. View Article : Google Scholar : PubMed/NCBI
2	Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP and Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature. 456:470–476. 2008. View Article : Google Scholar : PubMed/NCBI
3	Pan Q, Shai O, Lee LJ, Frey BJ and Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 40:1413–1415. 2008. View Article : Google Scholar : PubMed/NCBI
4	Venables JP: Aberrant and alternative splicing in cancer. Cancer Res. 64:7647–7654. 2004. View Article : Google Scholar : PubMed/NCBI
5	Kim E, Goren A and Ast G: Insights into the connection between cancer and alternative splicing. Trends Genet. 24:7–10. 2008. View Article : Google Scholar : PubMed/NCBI
6	Oltean S and Bates DO: Hallmarks of alternative splicing in cancer. Oncogene. 33:5311–5318. 2014. View Article : Google Scholar : PubMed/NCBI
7	Liu S and Cheng C: Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA. 4:547–566. 2013. View Article : Google Scholar : PubMed/NCBI
8	De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
9	Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, Guo W, Xing Y and Carstens RP: An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 29:3286–3300. 2010. View Article : Google Scholar : PubMed/NCBI
10	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
11	Hudler P: Genetic aspects of gastric cancer instability. Sci World J. 2012:7619092012. View Article : Google Scholar
12	Tao J, Deng NT, Ramnarayanan K, Huang B, Oh HK, Leong SH, Lim SS, Tan IB, Ooi CH, Wu J, et al: CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med. 3:77ra302011. View Article : Google Scholar : PubMed/NCBI
13	Zouridis H, Deng N, Ivanova T, Zhu Y, Wong B, Huang D, Wu YH, Wu Y, Tan IB, Liem N, et al: Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 4:156ra1402012. View Article : Google Scholar : PubMed/NCBI
14	Calcagno DQ, Gigek CO, Chen ES, Burbano RR and Smith MA: DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol. 19:1182–1192. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
16	Li T, Mo X, Fu L, Xiao B and Guo J: Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget. 7:8601–8612. 2016.PubMed/NCBI
17	Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 5:845–856. 2005. View Article : Google Scholar : PubMed/NCBI
18	Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, et al: Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 32:644–652. 2014. View Article : Google Scholar : PubMed/NCBI
19	Li XW, Shi BY, Yang QL, Wu J, Wu HM, Wang YF, Wu ZJ, Fan YM and Wang YP: Epigenetic regulation of CDH1 exon 8 alternative splicing in gastric cancer. BMC Cancer. 15:9542015. View Article : Google Scholar : PubMed/NCBI
20	Hafezi N, Ajami A, Farazmandfar T, Hosseini V, Alizadeh-Navaei R and Tehrani M: Increased expression of two alternative spliced variants of CD1d molecule in human gastric cancer. Iran J Immunol. 12:129–140. 2015.PubMed/NCBI
21	Tsai YS, Dominguez D, Gomez SM and Wang Z: Transcriptome-wide identification and study of cancer-specific splicing events across multiple tumors. Oncotarget. 6:6825–6839. 2015. View Article : Google Scholar : PubMed/NCBI
22	Armero VE, Tremblay MP, Allaire A, Boudreault S, Martenon-Brodeur C, Duval C, Durand M, Lapointe E, Thibault P, Tremblay-Létourneau M, et al: Transcriptome-wide analysis of alternative RNA splicing events in Epstein-Barr virus-associated gastric carcinomas. PLoS One. 12:e01768802017. View Article : Google Scholar : PubMed/NCBI
23	Uozaki H and Fukayama M: Epstein-Barr virus and gastric carcinoma - viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol. 1:198–216. 2008.PubMed/NCBI
24	Ryan M, Wong WC, Brown R, Akbani R, Su X, Broom B, Melott J and Weinstein J: TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 44:D1018–D1022. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ryan MC, Cleland J, Kim R, Wong WC and Weinstein JN: SpliceSeq: A resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics. 28:2385–2387. 2012. View Article : Google Scholar : PubMed/NCBI
26	Lex A, Gehlenborg N, Strobelt H, Vuillemot R and Pfister H: UpSet: Visualization of intersecting sets. IEEE Trans Vis Comput Graph. 20:1983–1992. 2014. View Article : Google Scholar : PubMed/NCBI
27	Sobin LH, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. 7th edition. Wiley-Blackwell; Oxford: pp. 3102009
28	Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 121:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
29	Jiang L, Deng J, Zhu X, Zheng J, You Y, Li N, Wu H, Lu J and Zhou Y: CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res. 14:R1052012. View Article : Google Scholar : PubMed/NCBI
30	Wu XM, Yang HG, Zheng BA, Cao HF, Hu ZM and Wu WD: Functional genetic variations at the microRNA binding-site in the CD44 gene are associated with risk of colorectal cancer in Chinese populations. PLoS One. 10:e01275572015. View Article : Google Scholar : PubMed/NCBI
31	Suenaga M, Yamada S, Fuchs BC, Fujii T, Kanda M, Tanaka C, Kobayashi D, Fujiwara M, Tanabe KK and Kodera Y: CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. J Surg Oncol. 112:622–628. 2015. View Article : Google Scholar : PubMed/NCBI
32	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
33	Sharma S and Lichtenstein A: Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood. 114:4179–4185. 2009. View Article : Google Scholar : PubMed/NCBI
34	Sharma S, Liao W, Zhou X, Wong DT and Lichtenstein A: Exon 11 skipping of E-cadherin RNA downregulates its expression in head and neck cancer cells. Mol Cancer Ther. 10:1751–1759. 2011. View Article : Google Scholar : PubMed/NCBI
35	Li X, Gao Y, Pan Y, Pan Y, Wang L, Xiao N, He Q, Fan Y and Wang Y: Mutation screen and RNA analysis disclose the changed splicing of the E-cadherin transcription in gastric cancer. Fam Cancer. 12:547–554. 2013. View Article : Google Scholar : PubMed/NCBI
36	Ruvinsky I and Meyuhas O: Ribosomal protein S6 phosphorylation: From protein synthesis to cell size. Trends Biochem Sci. 31:342–348. 2006. View Article : Google Scholar : PubMed/NCBI
37	Kim SH, Jang YH, Chau GC, Pyo S and Um SH: Prognostic significance and function of phosphorylated ribosomal protein S6 in esophageal squamous cell carcinoma. Mod Pathol. 26:327–335. 2013. View Article : Google Scholar : PubMed/NCBI
38	Chen B, Tan Z, Gao J, Wu W, Liu L, Jin W, Cao Y, Zhao S, Zhang W, Qiu Z, et al: Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer. J Exp Clin Cancer Res. 34:1262015. View Article : Google Scholar : PubMed/NCBI
39	Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN and Arun B: Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 9:1180–1187. 2010. View Article : Google Scholar : PubMed/NCBI
40	Pagano M: Cell cycle regulation by the ubiquitin pathway. FASEB J. 11:1067–1075. 1997. View Article : Google Scholar : PubMed/NCBI
41	Xie C, Powell C, Yao M, Wu J and Dong Q: Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar : PubMed/NCBI
42	Lee SW, Han SI, Kim HH and Lee ZH: TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. J Biochem Mol Biol. 35:371–376. 2002.PubMed/NCBI
43	Yamaguchi T, Miyashita C, Koyano S, Kanda H, Yoshioka K, Shiba T, Takamatsu N and Ito M: JNK-binding protein 1 regulates NF-kappaB activation through TRAF2 and TAK1. Cell Biol Int. 33:364–368. 2009. View Article : Google Scholar : PubMed/NCBI
44	Fu L, Shi J, Hu K, Wang J, Wang W and Ke X: Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia. Oncotarget. 6:8144–8154. 2015. View Article : Google Scholar : PubMed/NCBI
45	Matera AG and Wang Z: A day in the life of the spliceosome. Nat Rev Mol Cell Biol. 15:108–121. 2014. View Article : Google Scholar :
46	Matlin AJ, Clark F and Smith CW: Understanding alternative splicing: Towards a cellular code. Nat Rev Mol Cell Biol. 6:386–398. 2005. View Article : Google Scholar : PubMed/NCBI
47	Naftelberg S, Schor IE, Ast G and Kornblihtt AR: Regulation of alternative splicing through coupling with transcription and chromatin structure. Annu Rev Biochem. 84:165–198. 2015. View Article : Google Scholar : PubMed/NCBI
48	Alló M, Buggiano V, Fededa JP, Petrillo E, Schor I, de la Mata M, Agirre E, Plass M, Eyras E, Elela SA, et al: Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struct Mol Biol. 16:717–724. 2009. View Article : Google Scholar : PubMed/NCBI
49	Makeyev EV, Zhang J, Carrasco MA and Maniatis T: The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell. 27:435–448. 2007. View Article : Google Scholar : PubMed/NCBI
50	Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R and Oberdoerffer S: CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature. 479:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
51	Danan-Gotthold M, Golan-Gerstl R, Eisenberg E, Meir K, Karni R and Levanon EY: Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res. 43:5130–5144. 2015. View Article : Google Scholar : PubMed/NCBI